Overall rank by patents
#32,077
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Immunomic Therapeutics, Inc.
USPTO PatentsView assignee record - 8 granted patents across 4 technology areas, active 2017–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C07K (PEPTIDES).
8
Total patents granted
4
CPC technology areas
23.6
Avg claims per patent
+200%
5-year filing velocity
The verdict
Immunomic holds 8 US patents across 4 technology areas, rank #32,077 of 50,000 tracked assignees.
- #32,077
- of 50,000 US assignees by volume
- Top 16%
- by Innovation Score (48.8/100)
- 23.6
- avg claims per patent
- +200%
- filing velocity, last 5 yrs
Portfolio overview
Immunomic Therapeutics, Inc. has been granted 8 US utility patents between 2017 and 2025, placing Immunomic Therapeutics, Inc. at rank #32,077 across all assignees tracked by PlainPatent. This portfolio spans 4 distinct Cooperative Patent Classification (CPC) subclasses, averaging 23.6 claims per patent with primary concentration in C07K (PEPTIDES). As a US Corporation, Immunomic Therapeutics, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Immunomic sits between Imageware Systems Inc. (8 patents, rank #32,073) and Implicit, Llc (8 patents, rank #32,081) - the closest US assignees by grant volume. The composite Innovation Score of 48.8/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 6 grants, compared with 2 in the 2015–2019 window, a +200% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Immunomic Therapeutics, Inc.'s 23.6 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while specialization in 4 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Immunomic Therapeutics, Inc. against peers pursuing similar technology classes.
Who files at Immunomic's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Imageware Systems
ImageWare Systems Inc.
8 patents
- Imerys Filtration…
Imerys Filtration Minerals, Inc.
8 patents
- Immatics US
Immatics US, INC.
8 patents
- Immunext
ImmuNext, Inc.
8 patents
- Imperative Chemic…
Imperative Chemical Partners Inc.
8 patents
- Imperial Pools
Imperial Pools, Inc.
8 patents
- Implant Sciences
Implant Sciences Corporation
8 patents
- Implicit
Implicit, LLC
8 patents
- Immunomic Therape… ◀
Immunomic Therapeutics, Inc.
8 patents
What this shows Immunomic holds 8 patents at rank #32,077, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Immunomic
By rank, the assignees closest to #32,077 in granted patent volume.
- Imageware Systems Inc. #32,073 · 8 patents
- Imerys Filtration Minerals, Inc. #32,074 · 8 patents
- Immatics US, Inc. #32,075 · 8 patents
- Immunext, Inc. #32,076 · 8 patents
- Imperative Chemical Partners Inc. #32,078 · 8 patents
- Imperial Pools, Inc. #32,079 · 8 patents
- Implant Sciences Corporation #32,080 · 8 patents
- Implicit, Llc #32,081 · 8 patents
Leaders in C07K (Peptides)
Other assignees with the most granted patents in Immunomic's primary technology class.
- The Regents Of The University Of California 894 in class
- Regeneron Pharmaceuticals, Inc. 824 in class
- Immatics Biotechnologies Gmbh 678 in class
- Genentech, Inc. 565 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 513 in class
- The Trustees Of The University Of Pennsylvania 501 in class
- Novartis Ag 407 in class
- The Board Of Trustees Of The Leland Stanford Junior University 400 in class
Immunomic's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
49 Top 16% higher than 84% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2017 | 1 | 12.5% |
| 2018 | 1 | 12.5% |
| 2021 | 1 | 12.5% |
| 2023 | 2 | 25.0% |
| 2024 | 1 | 12.5% |
| 2025 | 2 | 25.0% |
Which technologies does Immunomic Therapeutics, Inc. patent most?
Top 4 of 4 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Complex
Velocity Accelerating
Frequently Asked Questions
How many patents does Immunomic Therapeutics, Inc. hold?
Immunomic Therapeutics, Inc. holds 8 US granted patents filed between 2017 and 2025, spanning 4 technology areas.
What is Immunomic Therapeutics, Inc.'s Innovation Score?
Immunomic Therapeutics, Inc. has an Innovation Score of 48.8 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Immunomic Therapeutics, Inc. focus on?
Immunomic Therapeutics, Inc.'s top technology area is C07K (PEPTIDES) with 8 patents. The company has filed patents in 4 CPC subclasses total.
Is Immunomic Therapeutics, Inc.'s patent filing rate increasing or decreasing?
Immunomic Therapeutics, Inc.'s recent filing velocity is +200% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for Immunomic Therapeutics, Inc.'s patents?
Immunomic Therapeutics, Inc.'s patents average 23.6 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Immunomic Therapeutics, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Immunomic's 8 grants land it in the top 16% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Immunomic ranks #32,077 of 50,000. Top 50 holders
- Most of this portfolio concentrates in C07K - see who else leads that technology area. C07K leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.